EP1237849A1 - Activateurs de la guanylate cyclase soluble - Google Patents

Activateurs de la guanylate cyclase soluble

Info

Publication number
EP1237849A1
EP1237849A1 EP00973061A EP00973061A EP1237849A1 EP 1237849 A1 EP1237849 A1 EP 1237849A1 EP 00973061 A EP00973061 A EP 00973061A EP 00973061 A EP00973061 A EP 00973061A EP 1237849 A1 EP1237849 A1 EP 1237849A1
Authority
EP
European Patent Office
Prior art keywords
dimethylamino
propyl
phenyl
chloro
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00973061A
Other languages
German (de)
English (en)
Inventor
David Uni College London The Wolfson SELWOOD
Robert Uni College London The Wolfson GLEN
Karen Uni College London The Wolfson REYNOLDS
Grant Uni College London The Wolfson WISHART
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9926286.7A external-priority patent/GB9926286D0/en
Application filed by University College London filed Critical University College London
Publication of EP1237849A1 publication Critical patent/EP1237849A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/37—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/40—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/62—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/38—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/50—Pyrenes; Hydrogenated pyrenes

Definitions

  • This invention relates to activators of soluble guanylate cyclase (sGC), to their preparation and to their use.
  • sGC soluble guanylate cyclase
  • Soluble guanylate cyclase is responsible for the enzymatic conversion of guanosine-5'-triphosphate (GTP) to cyclic guanosine-3',5'-monophosphate (cGMP).
  • sGC is responsible for numerous physiological processes including vascular and non-vascular smooth muscle relaxation, peripheral and central neurotransmission, platelet reactivity and phototransduction (Hobbs A.J., TiPS, December 1997, Vol 18, p.484). Activators of sGC can therefore be expected to have valuable therapeutic properties.
  • NO is known as an activator of sGC.
  • this compound has a number of different physiological effects and its use in activating sGC therefore suffers from a myriad of side effects. There is therefore a need for selective activators of sGC.
  • 3-(5'-hydroxymethyl-2'-furyl)-l-benzylindazole (YC-1) is a known NO independent activator of sGC (Hobbs, A.J., TiPS, December 1997, Vol 18, p.484). However, the activation achieved is not high.
  • the present invention provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the activation of soluble guanylate cyclase
  • R, and R 2 are the same or different and each represent a C,-C 6 alkyl group, or R, and R 2 together form a C 3 -C 6 alkylene group;
  • Z is a C,-C 4 alkylene group
  • P is a direct bond or a moiety -X-, -Y-, -W-, -XY-, -YW- or -XYW-, wherein:
  • R 4 is C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C,-C 6 alkyl)-, -(C 2 -C alkenyl)- or -(C 2 -C 6 alkynyl)- and A is aryl, heteroaryl, carbocycyl or heterocyclyl, or R 4 is a group -COR' * ', -CO ⁇ , -S(O) 2 R or -CONR'R" wherein R' is hydrogen, C r C 6 alkyl, C 2 -C 6 alkenyl or
  • C 2 -C 6 alkynyl and R" is is aryl, heteroaryl, carbocyclyl or heterocyclyl.
  • the moiety -X- when present, is attached to R 4 and the moiety W, when present, is attached to Z.
  • the moiety Y the moiety V is attached to W or, if W is not present, to Z, and the moiety U is attached to X or, if X is not present, to R 4 .
  • a C,-C 6 alkyl group or moiety is a linear or branched alkyl group or moiety.
  • Suitable alkyl groups and moieties include C r C 4 alkyl groups and moieties, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl. Methyl, ethyl, n-propyl and t-butyl are preferred.
  • a C r C 6 alkyl group or moiety can be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1, 2 or 3 substituents. Suitable substituents include C r C 6 alkyl, C r C 6 alkylthio, C r C 6 alkoxy, C,-C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, oxo, -NR / R wherein R 7 and R" are the same or different and are hydrogen or C r C 6 al
  • two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
  • two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C 3 -C 6 cycloalkyl group.
  • a C 2 -C 6 alkenyl group or moiety is a linear or branched alkenyl group or moiety.
  • Suitable alkenyl groups and moieties include C 2 -C 4 alkenyl groups and moieties such as ethenyl, propenyl and butenyl groups and moieties. Ethenyl and propenyl are preferred.
  • a C 2 -C 6 alkenyl group or moiety may be substituted or unsubstituted at any position.
  • a C 2 -C 6 alkenyl group is typically unsubstituted or carries 1, 2, 3 or 4 substituents. Preferably, it carries at least two substituents. Suitable substituents include oxo, C r C 6 alkyl, C r C 6 alkylthio, C r C 6 alkoxy, C]-C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR'R" wherein R' and R / are the same or different and are hydrogen or C r C 6 alkyl,
  • two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C 3 -C 8 cycloalkyl group.
  • substituents are halogen, for example chlorine and fluorine, C r C 4 alkyl, for example methyl, ethyl or t-butyl, aryl, for example phenyl, heteroaryl, for example furanyl, -CONH-aryl, for example -CONH-phenyl, -NH- CO 2 -(C,-C 4 alkyl), -NH-CO-(C,-C 4 alkyl), -NH-CO-aryl, for example -NH-CO- phenyl, heteroarylthio, for example pyrimidinethio and -CO-aryl, for example -CO- phenyl. It is also preferred that two substituents on the same carbon atom may, together with the atom to which they are attached, form a C 3 -C 8 cycloalkyl group.
  • a C 2 -C 6 alkynyl group or moiety is typically an ethynyl, propynyl or butynyl group or moiety. It may be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1 or 2 substituents.
  • Suitable substituents include C r C 6 alkyl, C,-C 6 alkylthio, C r C 6 alkoxy, C r C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR / R / wherein R' and R / are the same or different and are hydrogen or C r C 6 alkyl, -
  • each R / can be the same or different and represents hydrogen or C r C 6 alkyl and each R can be the same or different and represents C r C 6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C r C 6 alkyl)-R // and -O-(Cj-C 6 alkyl)-R wherein each R" 1 can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl.
  • two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
  • Preferred substituents include halogen, C r C 6 alkyl, aryl, arylthio, aryloxy, heteroaryl, heteroarylthio, heteroaryloxy and -CONHR and -NHCO 2 R wherein R is as defined above.
  • two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C 3 -C 6 cycloalkyl group.
  • substituents are halogen, for example chlorine and fluorine, C r C 4 alkyl, for example methyl, ethyl or t-butyl, aryl, for example phenyl, -CONH-aryl, for example -CONH-phenyl, -NH-CO 2 -(C ,-C 4 alkyl), heteroarylthio, for example pyrimidinethio and -CO-aryl, for example -CO-phenyl. It is also preferred that two substituents on the same carbon atom may, together with the atom to which they are attached, form a C 3 -C 6 cycloalkyl group.
  • a C,-C 6 alkoxy group is typically a said C,-C 6 alkyl group attached to an oxygen atom.
  • a C,-C 6 alkylthio group is typically a said C,-C 6 alkyl group attached to a sulphur atom.
  • a said alkylene group is a divalent alkyl moiety. It may be unsubstituted or substituted at any position. Typically, it is unsubstituted or monosubstituted. Suitable substituents include halogen, for example chlorine and flourine, hydroxy, C C 4 alkyl such as methyl and ethyl, C C alkoxy, for example methoxy, C r C 4 haloalkyl, for example -CF 3 and -CC1 3 and C r C 4 haloalkoxy, for example -OCF 3 and -OCCl 3 . These substituents are typically themselves unsubstituted.
  • a halogen is typically chlorine, fluorine, bromine or iodine. It is preferably chlorine.
  • a haloalkyl or haloalkoxy group is typically a said alkyl or alkoxy group substituted by one or more said halogen atoms. Typically, it is substituted by 1, 2 or 3 said halogen atoms.
  • Preferred haloalkyl and haloalkoxy groups include perhaloalkyl and perhaloalkoxy groups such as -CX 3 and -OCX 3 wherein X is a said halogen atom.
  • Particularly preferred haloalkyl groups are CF 3 and CC1 3 .
  • Particularly preferred haloalkoxy groups are -OCF 3 and -OCCl 3 .
  • an aryl group or moiety is typically a C 6 -C 20 aryl group or moiety. Suitable such aryl groups and moieties include phenyl, naphthyl and pyrenyl. Phenyl and pyrenyl are preferred.
  • An aryl group or moiety may be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1, 2, 3 or 4 substituents. Suitable substituents include C,-C 6 alkyl, C r C 6 alkylthio, C r C 6 alkoxy, C r C 6 haloalkyl, for example -CF 3 and -CC1 3 , - haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, cyano, hydroxy, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NRR wherein R' and R" are the same or different and are hydrogen or C,-C 6 alkyl, -COR, -CONR /
  • Preferred substituents include C C 6 alkyl, for example methyl and ethyl, C r C 6 alkoxy, for example methoxy, C r C 6 alkylthio, for example methylthio, C,-C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, for example chlorine and fluorine, nitro, cyano, aryl, for example phenyl, aryloxy, for example phenyloxy, arylthio, for example phenylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, -NRR / wherein R f and R are the same or different and are hydrogen or C,-C 6 alkyl, -CONH-(C,-C 6 alkyl), -NHCONH-R wherein R is aryl, for example phen
  • substituents are phenyl, in particular 4-phenyl, phenoxy, in particular 2-phenoxy, phenylthio, halogen, -CF 3 , -CC1 3 , nitro, cyano, -OCF 3 , -OCCl 3, C,-C 4 alkyl, C,-C 4 alkoxy, C,-C 4 alkylthio, -CONH-(C,-C 4 alkyl),
  • An aryl group or moiety may be fused to a further said aryl group or to a carbocyclic, heterocyclic or heteroaryl group.
  • an aryl group may be fused to a pyridine ring to form a quinoline or isoquinoline group, or to a furan ring. It may also, for example, be fused to a cyclopropyl or cyclohexyl group or to a tetrahydro furyl group, a 1,4-dioxolane group or a pyrimidone ring, for example a 4- pyrimidone ring.
  • a carbocyclic group or moiety is a non-aromatic, saturated or unsaturated carbocyclic group or moiety. Typically, it has from 3 to 10, for example from 3 to 8, carbon atoms. Preferably, it has from 3 to 8, for example 3 to 6, carbon atoms.
  • suitable carbocyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclopetadienyl, cyclohexyl, cyclohexenyl and cyclooctanyl groups.
  • Preferred carbocyclic groups include cyclohexyl, cyclooctanyl and cyclohexenyl groups.
  • substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
  • Preferred substituents include oxo, C,-C 6 alkyl, for example methyl and ethyl, C r C 6 alkoxy, for example methoxy, C,-C 6 alkylthio, for example methylthio, C,-C 6 haloalkyl, for example -CF 3 and -CC1 3 , - haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, for example chlorine and fluorine, nitro, cyano, aryl, for example phenyl, aryloxy, for example phenyloxy, arylthio, for example phenythio, heteroaryl, heteroarylthio, heterocyclyl, -CONH-(C,-C 6 alkyl), -NHCONH-R wherein R is aryl
  • a carbocyclic group or moiety may be fused to a further carbocyclic group or to an aryl, heteroaryl or heterocyclic group.
  • a heteroaryl group or moiety is typically a 5- to 10- membered aryl ring containing at least one heteroatom, for example 1, 2 or 3 heteroatoms, selected from
  • the heteroaryl group or moiety is a 5- or 6- membered ring.
  • Suitable heteroaryl groups and moieties include pyridyl, pyranyl, furanyl, thienyl, pyrazolidinyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl, pyrazolyl, iso thiazolyl, isoxazolyl, furazanyl, triazolyl and thiadiazolyl groups.
  • a heteroaryl group or moiety may be unsubstituted or substituted at any position. Typically, it is unsubstituted or carries up to three substituents. Suitable substituents include C r C 6 alkyl, C r C 6 alkylthio, C,-C 6 alkoxy, C,-C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR / R / wherein R ; and R // are the same or different and are hydrogen or C r C 6 alkyl, -COR,
  • each R can be the same or different and represents hydrogen or C r C 6 alkyl and each R can be the same or different and represents C r C 6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C 6 alkyl)-R and -O-(C 1 -C 6 alkyl)-R / wherein each R"' can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl.
  • Preferred substituents include C r C 6 alkyl, for example methyl and ethyl,
  • C r C 6 alkoxy for example methoxy, C r C 6 alkylthio, for example methylthio, C r C 6 haloalkyl, for example -CF 3 and -CC1 3 , C,-C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, for example chlorine, cyano, nitro, aryl, for example phenyl, aryloxy, for example phenoxy, arylthio, for example phenylthio and -O-(C,-C 6 alkyl)-R, -S-(C,-C 6 alkyl)-R, -S-(C,-C 6 alkyl)-CONH-R, -CO-R and
  • R is an aryl group, for example a phenyl group.
  • substituents include phenyl, halogen, for example chlorine, C r C 4 alkyl, for example methyl, -CF 3 , -CC1 3 , -OCF 3 , -OCCl 3 , phenylthio, phenoxy, -S-(C C 4 alkyl)-CONH-phenyl, -S-(C,-C 4 alkyl)-phenyl, -O-(C r C 4 alkyl)-phenyl, -CO-phenyl, cyano, C r C 4 alkylthio, nitro,
  • a heteroaryl group may be fused to a said aryl or carbocyclic group or to a further heteroaryl group or to a heterocyclic group.
  • fused heteroaryl groups include quinolyl, indolyl, isoindolyl, benzothiophenyl, imidazo[l,2- ]pyridyl and ⁇ -carbolinyl groups.
  • a heterocyclic group or moiety is a non-aromatic, saturated or unsaturated cyclic group or moiety containing at least one, for example, one, two or three, heteroatoms selected from N, O and S. Typically, it is a 3- to 6- membered ring. Preferably, it is a 5- or 6- membered ring containing, as heteroatoms, one or two nitrogen atoms.
  • Suitable heterocyclic groups and moieties include pyrazolidinyl, piperidyl, piperazinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolinyl, 3,4-dihydro-2H-pyranyl, tetrahydropyrimidinyl (for example 1,2,3,4- or 1,4,5,6- tetrahydrapyrimidinyl), 2-hydropyridinyl, 2-hydrothiazolyl, tetrahydropyridinyl (for example 1,2,5,6- or 2,3,4,5-tetrahydropyridinyl) and tetrahydropyridazinyl, for example 3 ,4,5 ,6-tetrahydropyridazinyl.
  • a heterocyclic group or moiety may be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1, 2, 3, 4 or 5 substituents. Suitable substituents include oxo, C C 6 alkyl, C,-C 6 alkylthio, C r C 6 alkoxy, C r C 6 haloalkyl, for example -CF 3 and -CC1 3 , C r C 6 haloalkoxy, for example -OCF 3 and -OCCl 3 , halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NRR / wherein R' and R /; are the same or different and are hydrogen or C,-C 6 alkyl,
  • a heterocyclic group or moiety may be fused to a further said heterocyclic group or to a said carbocyclic, aryl or heteroaryl group. Typically, it is non- fused or is fused to a benzene ring or to an iodole group. Examples of such fused heterocyclic groups include chromanyl and chromonyl groups.
  • An aryloxy, heteroaryloxy, heterocyclyloxy or carbocyclyloxy group is typically a said aryl, heteroaryl, heterocyclyl or carbocyclyl group attached to an oxygen atom.
  • An arylthio, heteroarylthio, heterocyclylthio or carbocyclylthio group is typically a said aryl, heteroaryl, heterocyclyl or carbocyclyl group attached to a sulphur atom.
  • R, and R 2 are the same or different and represent methyl, ethyl, propyl, n-butyl or t-butyl.
  • the groups represented by R, and R 2 are unsubstituted or carry one or two substituents.
  • substituents for R, and R 2 include C r C 4 alkyl, for example methyl and ethyl, C,-C alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, Cj-C 4 haloalkyl, for example -CF 3 and -CC1 3 and C,-C 4 haloalkoxy, for example -OCF 3 and -OCCl 3 Typically, these substituents are themselves unsubstituted.
  • R, and R 2 are methyl or Rj and R 2 together form a n-butylene group.
  • Z is methylene, ethylene, propylene or butylene and is preferably propylene.
  • Z is unsubstituted, monosubstituted or disubstituted.
  • Preferred substituents for Z include C r C 4 alkyl, for example methyl and ethyl, C r C 4 alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, C C 4 haloalkyl, for example -CF 3 and -CC1 3 and C,-C 4 haloalkoxy, for example -OCF 3 and -OCCl 3 .
  • these substituents are themselves unsubstituted.
  • Particularly preferred substituents for Z are C r C 4 alkyl groups, in particular methyl groups.
  • a preferred substituted alkylene group is 2,2-dimethylpropylene.
  • the moiety P is -Y-, -XY-, -YW- or -XY -.
  • the moiety P is -XYW- or -YW-.
  • P is typically an aryl, heteroaryl or heterocyclyl moiety and/or is typically substituted by an aryl, heteroaryl, heterocyclyl or carbocyclyl substituent.
  • W is -O- or -NR 3 .
  • R 3 is hydrogen or is methyl, ethyl, propyl, n-butyl or t-butyl.
  • R 3 is unsubstituted or carries one or two substituents.
  • Preferred substituents for R 3 include C,-C 4 alkyl, for example methyl and ethyl, Cj-C 4 alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, C r C 4 haloalkyl, for example -CF 3 and -CC1 3 and C C 4 haloalkoxy, for example -OCF 3 and -OCCl 3 .
  • these substituents are themselves unsubstituted.
  • R 3 is hydrogen or methyl, most preferably hydrogen.
  • V is preferably a direct bond.
  • X is typically -NRg-.
  • R 6 is typically C r C 4 alkyl, for example methyl, ethyl, propyl, n-butyl and t-butyl, aryl, for example phenyl, or heteroaryl, for example pyridyl.
  • R ⁇ is unsubstituted or carries 1, 2 or 3 substituents.
  • substituents for R 6 include C r C 4 alkyl, for example methyl and ethyl, C r C 4 alkoxy such as methoxy or ethoxy, halogen, for example fluorine or chlorine, C,-C 4 haloalkyl, for example -CF 3 and -CC1 3 , C,-C 4 haloalkoxy, for example -OCF 3 and -OCCl 3 , cyano, nitro and -NRR / wherein R' and R" are the same or different and are hydrogen or C r C alkyl. Typically, these substituents are themselves unsubstituted.
  • X is -NH-.
  • the group R 4 has up to 30 carbon atoms and up to 10 heteroatoms selected from N, O and S. Preferably, it has up to 25 carbon atoms and up to 7 heteroatoms.
  • the group R 4 contains at least one, preferably at least two, aryl or heteroaryl rings.
  • R 4 is C r C 6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -(C,-C 6 alkyl)-aryl, -(C,-C 6 alkyl)-heteroaryl or -COR", -CO 2 R" or -CONR'R" wherein R' is hydrogen or C r C 6 alkyl and R" is an aryl, heteroaryl, carbocyclyl or heteroaryl group.
  • R 4 is not a moiety (A) or (B).
  • R is: hydrogen, aryl, heteroaryl, 3- to 6- membered heterocyclyl, -(C r C 4 alkyl)-R wherein R is aryl, heteroaryl or 3- to 6- membered heterocyclyl, C r C 4 alkyl, -CONA' 2 , -COA" or -SO 2 A" wherein each A' is the same or different and is selected from H, C,-C 4 alkyl and aryl and each A" is the same or different and is selected from C C 4 alkyl and aryl; and R' 3 and R' 4 are either:
  • R 4 is not a 3- or 5- pyrazole or a 3- indazole group when P is a direct bond, -O- or -NH-. More preferably R 4 is not a pyrazole or indazole group when P is a direct bond, -O- or -NH-. More typically, R 4 is not a 3- or 5- pyrazole or a 3- indazole group or, more preferably, a pyrazole or indazole group when P does not contain the moiety U.
  • R 4 is a pyridyl, pyrimidyl, thiazolyl or thienyl group.
  • R 4 is typically also a pyridyl, pyrimidyl, thiazolyl or thienyl group when P does not contain the moiety U and R 4 is a heteroaryl group.
  • Suitable pyridyl, pyrimidyl, thiazolyl and thienyl groups include groups fused to a said aryl or said carbocyclic group or to a said heteroaryl or said heterocyclic group.
  • R may be substituted by one or more of the groups mentioned above as appropriate substituents for R 4 .
  • Preferred compounds of the invention are those in which X is -NRg- wherein R is as defined above, and R 4 is aryl or heteroaryl.
  • P is typically -XYW-.
  • Y is typically -CO-.
  • W is typically -NR 3 - wherein R 3 is as defined above.
  • X is preferably -NH- and/or R 4 is preferably phenyl, thienyl or pyrazolyl.
  • R 4 when R 4 is phenyl it is typically substituted by a phenoxy group or by a phenylthio group, in particular a 2-phenoxy or 2-phenylthio group, or by a further phenyl group, in particular a 4-phenyl group.
  • R 4 when R 4 is thienyl or pyrazolyl, it is typically substituted by a phenyl or phenylthio group.
  • substituents may be unsubstituted or may be further substituted at any position. Typically, they are unsubstituted or carry one, two or three further substituents.
  • Preferred further substituents include halogen, for example chlorine and fluorine, C r C alkyl, for example methyl and ethyl, C r C 4 alkoxy, for example methoxy and ethoxy, C,-C 4 haloalkyl, for example -CF 3 and -CC1 3 , and -S(O) 2 NH-phenyl.
  • R 4 is preferably
  • P is -YW- and R 4 is an aryl, heterocyclyl or heteroaryl group.
  • Y is typically -CO-.
  • W is typically -NR 3 - wherein R 3 is as defined above.
  • R 4 is preferably an oxo-substituted heterocyclic group such as a chromonyl group or is a pyrazolyl, thienyl, phenyl or indolyl group.
  • R 4 is typically unsubstituted or substituted by one or more, for example, one, two or three substituents selected from
  • C,-C 6 alkyl for example t-butyl, phenyl, thiazolyl, phenylthio, cyano, nitro, C r C 6 alkylthio, for example i-propylthio, C r C 6 alkoxy, halogen such as chlorine and -S-(C C 4 alkyl)-phenyl.
  • substituents may be unsubstituted or may be substituted at any position. Typically, they are unsubstituted or carry one, two or three further substituents.
  • Preferred further substituents include halogen, for example chlorine, C r C 4 haloalkyl, for example -CF 3 , phenyl and -S(O) 2 -NH-phenyl. These further substituents are typically themselves unsubstituted.
  • Additional preferred compounds of the invention are those in which P is -W- or -YW- wherein Y is -CO- and W is -O-.
  • Particularly preferred compounds of the invention are compounds of formula
  • R ! and R 2 are the same or different and each represent a C r C 6 alkyl group, or Rj and R 2 together form an alkylene group having from 3 to . 6 carbon atoms;
  • Z is an alkylene group having from 2 to 4 carbon atoms;
  • R 3 is hydrogen or C r C 6 alkyl;
  • Y is -CO- or -S(O) 2 -;
  • X is a direct bond or -NR ⁇ - wherein R 6 is hydrogen, C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl or heteroaryl; and
  • R 4 is C,-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C,-C 6 alkyl)-, -(C 2 -C 6 alkenyl)- or -(C 2 -C 6 alkynyl)- and A is aryl, heteroaryl, carbocycyl or heterocyclyl, or R 4 is a group -COR' or -CO 2 R' wherein R' is aryl, heteroaryl, carbocyclyl or heterocyclyl.
  • Rj and R are methyl or together form a n-butylene group
  • R 3 is hydrogen or methyl
  • R 4 is as defined in the formula (I) or in the formula (I 7 ) and X is a direct bond or is -NRg- wherein R 6 is as defined above.
  • R 4 is as defined as in the above preferred compounds of the invention.
  • R 4 is as defined in the above further preferred compounds of the invention.
  • the present invention includes pharmaceutically acceptable salts of the compounds of the invention.
  • Suitable salts include salts with pharmaceutically acceptable acids, both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succininc, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid. Salts may also be formed with pharmaceutically acceptable bases such as alkali metal (eg sodium or potassium) and alkali earth metal (eg calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines or heterocyclic amines.
  • inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid
  • organic acids such as citric, fumaric, maleic, malic, ascorbic, succininc
  • Particularly preferred compounds of the invention are: l-(3-Dimethylamino-propyl)-3-(2-phenoxy-phenyl)-urea l-[2-(4-Chloro-phenoxy)-pyridin-3-yl]-3-(3-dimethylaminopropyl)-urea l-(3-Dimethylamino-propyl)-3-pyren-l-ylmethyl-urea l-(3-Dimethylamino-propyl)-3-[(lR,2R)-5-phenyl-2-(l-phenyl-methanoyl)- cyclohexyl]-urea l-(3-Dimethylamino-propyl)-3-[2-(4-phenoxy-phenyl)-ethyl]-urea l-(3-Dimethylamino-propyl)-3-[3-methyl-5-(4-methyl-[l,2,3]thiadiazol-5- y
  • R 4 is as defined above and U' is a group -UL wherein U is as defined above and L is a hydroxy group or a leaving group such as a halogen atom.
  • Compounds of formulae (II) and (III) are known compounds, or may be prepared by analogy with known methods.
  • the reaction takes place in the presence of a base such as diisopropylethylamine or the equivalent polymer bound resin N,N- (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), and a coupling agent such as O-(7-azabenzotriazol- 1 -yl)-N,N, N, N-tetramethyluronium hexafluorophosphate (HATU).
  • a base such as diisopropylethylamine or the equivalent polymer bound resin N,N- (diisopropyl)amino-methylpolystyrene resin (PS-DIEA)
  • PS-DIEA polymer bound resin N,N- (diisopropyl)amino-methylpolystyrene resin
  • HATU O-(7-azabenzotriazol- 1 -yl)-N,N, N, N-tetramethyluronium hex
  • the work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting materials.
  • a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins.
  • R 4 is as defined above.
  • the reaction takes place in a hydrocarbon solvent such as toluene at a temperature of from 0 to 100 °C.
  • a hydrocarbon solvent such as toluene
  • the work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting materials.
  • the amides thereby prepared may be converted to the corresponding amidines by standard methods.
  • the compounds of formula (IV) may be prepared by techniques known in the art. For example, they may be prepared by reacting a compound of formula (V)
  • R 4 , X and U are as defined above and L is a hydroxy group or leaving group such as a 4-nitro-phenoxy group.
  • the reaction takes place in a hydrocarbon solvent such as tetrahydrofuran at a temperature of from 60 to 70 °C.
  • the work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting material.
  • the compounds of formula (NI) are known compounds or may be prepared by analogy with known methods.
  • compounds of formula (VI) in which U is -CO- can be prepared by reacting a compound of formula (VII)
  • a chloroformate for example an aromatic chloroformate such as 4-nitrophenyl chloroformate.
  • the reaction takes place under reflux, in a solvent such as anhydrous THF.
  • R 4 is other than -COR", -CO 2 R", S(O) 2 R" and -CONR'R" and X is as defined above, with a compound of formula (IX)
  • Y, Z, Rj and R 2 are as defined above and L represents a hydroxy group or a leaving group such as a halogen.
  • the reaction is typically conducted in the presence of a base at from -78°C to the reflux temperature of the solvent.
  • R , X and U are as defined above and L represents a hydroxy group or a leaving group such as a halogen, with a compound of formula (XI) HWZNR,R 2 (XI)
  • A is -X- or -W-, wherein X and W are as defined above and R 4 is other than -COR", -CO 2 R", -S(O) 2 R" and -CONR'R", with a compound of formula (XIII)
  • reaction can be conducted under standard conditions. Typically, it takes place in the presence of a base in a solvent such as
  • the compounds of formula (XII) are known compounds or may be prepared by analogy with known methods.
  • the compounds of formula (XIII) are also known compounds or may be prepared by analogy with known methods. For example, they can be prepared from a corresponding compound of formula HO-Z-NR ⁇ by reaction with triflic anhydride or with PC1 5 .
  • HA-Z-NR,R 2 (IXV) wherein A, Z, R, and R 2 are as defined above, with R 4 -L, wherein R ⁇ is as defined above and L is a hydroxy group or a leaving group, for example a halogen.
  • the reaction can be conducted under standard conditions, such as those given above for the reaction of compounds of formulae (Vffl) and (IX).
  • R 4 is aryl or heteroaryl, and a compound of formula (XVI)
  • L is a hydroxy group, a group OR wherein R is alkyl, or a halogen, for example chlorine, and Z, V, R ⁇ and R 2 are as defined above.
  • the reaction can be performed under conventional conditions, in the presence of a catalyst such as A1C1 3 .
  • R 4 is as defined above, Y' is -U- or -X-U-, and L is a hydroxy group or a leaving group, for example a halogen atom, with an organometallic compound of formula (XVIII)
  • B is -V-Z- wherein V and Z are as defined above, Rj and R 2 are as defined above and M is a metal-containing moiety such as Li or -MgX wherein X is a halogen atom such as bromine.
  • M in the formula (XVIII) is Li.
  • M in the formula (XVIII) is -MgX, it may be necessary to conduct the reaction at around -78 °C and to use a large excess of the compound of formula (XVII).
  • the compounds of formula (XVII) are known compounds or may be prepared by analogy with known methods.
  • the compounds of formula (XVIII) are also known compounds or may be prepared by analogy with known methods.
  • compounds of formula (XVIII) in which M is Li can be prepared by reacting a corresponding compound of formula Br-B-N ⁇ with lithium or with magnesium.
  • R 4 -P-L (IXX) wherein R 4 and P are as defined above and L is a leaving group such as a halogen atom or a triflate group, with a compound of formula (XX)
  • the reaction can be conducted under conventional conditions. Typically, it is conducted in the presence of a base. If necessary, the NR]R 2 group can be protected during the reaction by conventional means.
  • the compounds of formulae (IXX) and (XX) are knowN compounds, or may be prepared by analogy with known methods.
  • the compounds of formula (IXX) can be prepared by reacting a corresponding compound of formula R 4 -P-OH with triflic anhydride or PC1 5 .
  • Compounds in which P is a direct bond can be prepared by conventional synthetic techniques.
  • a compound of the invention can, of course, be converted to a different compound of the invention by standard functional group intercon versions known to those of skill in the art.
  • compositions of formula (I) may be prepared by salifying a compound of formula (I) with an appropriate acid or base.
  • the compounds of the invention are activators of sGC. They can be used as selective sGC activators.
  • a compound of the invention can therefore be used as a vasodilator or to inhibit platelet aggregation. It can be used for the treatment or prevention of peripheral vascular diseases such as hypertension, angina pectoris, arteriosclerosis, or for the treatment or prevention of glaucoma, preeclampsia, Raynaud's Syndrome, stroke or erectile dysfunction. Further, the compounds of the invention are effective in improving ocular blood flow.
  • ASD age-related macular degeneration
  • AMD age-related macular degeneration
  • sGC vascular endothelial growth factor
  • the present invention also provides a compound of formula (I), as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body, wherein R,, R 2 , Z, R 3 , Y, X and R 4 are as defined above.
  • the compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
  • the compounds of the invention may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques.
  • the compounds may also be administered as suppositories.
  • a compound of the invention is typically formulated for administration with a pharmaceutically acceptable carrier or diluent.
  • solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g.
  • Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film coating processes.
  • Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
  • the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginte, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
  • Solutions for intravenous or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
  • a therapeutically effective amount of a compound of the invention is administered to a patient.
  • a typical daily dose is from about 0.1 to 50 mg per kg of body weight, according to the activity of the specific compound, the age, weight and conditions of the subject to be treated , the type and severity of the disease and the frequency and route of administration.
  • daily dosage levels are from 5 mg to 2 g. The Examples which follow illustrate the invention.
  • Tetrafluorophthalic anhydride (65 mg, 0.3 mmol) was then added and the reaction mixture was shaken under nitrogen for 18 hours.
  • Macroporous triethylammonium methylpolystyrene carbonate resin (MP-carbonate), (610 mg, 1.96 mmol, loading 3.18 mmol/g) was then added and the reaction mixture was shaken under nitrogen for a further 48 hours.
  • the reactions were then filtered through filter syringes into vials and washed with methanol. The solvent was removed on a vacuum concentrator and each product was weighed and analysed by LC-MS.
  • Examples 70 to 99 The aryl acid (different for each reaction) (0.1 mmol) was stirred under nitrogen in anhydrous toluene (2 mL) and heated to 50 °C. Triethylamine (10 mg, 0.1 mmol) dissolved in 1 L of anhydrous toluene was then added. The temperature was raised to 80 °C and diphenylphosphorylazide (DPP A), (27.0 mg, 0.1 mmol) was added. The reaction was kept at this temperature for 1 hour then cooled to room temperature while still stirring under nitrogen.
  • DPP A diphenylphosphorylazide
  • the reaction mixture was cooled to room temperature and tetrafluorophthalic anhydride (191.0 mg, 0.87 mmol) was added.
  • the reaction was stirred at room temperature under nitrogen for 1 hour, then 6 equivalents of tris-(2-aminoethyl)amine polystyrene resin (PS-trisamine), (500 mg, 1.74 mmol, loading 3.5 mmol/g) was added and the reaction stirred for 2 hours.
  • PS-trisamine tris-(2-aminoethyl)amine polystyrene resin
  • Example 100 Prepared as in Example 100 using 4-nitrophenyl chloroformate (77.2 mg, 0.38 mmol), 4-bromoaniline (30.0 mg, 0.174 mmol) and triethylamine (38.8 mg, 0.38 mmol) to form the intermediate followed by 3-(dimethylamino)propylamine (26.6 mg, 0.26 mmol) to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using MeOH/CHCl 3 (40:60).
  • Example 100 Prepared as in Example 100 using 4-nitrophenyl chloroformate (87.0 mg, 0.436 mmol), 4-bromoaniline (50.0 mg, 0.29 mmol) and triethylamine (44.0 mg, 0.436 mmol) refluxed for 5 hours in anhydrous THF (20mL) to form the intermediate. Then N,N,N-trimethyl-l,3-propanediamine (50.5 mg, 0.436 mmol) was added and the reaction mixture refluxed for 18 hours to form the title compound. Work-up as in Example 100.
  • Example 100 Prepared as in Example 100 using 4-nitrophenyl chloroformate (45.5 mg, 0.226 mmol), 5-phenyl- ⁇ -anisidine (30.0 mg, 0.151 mmol) and triethylamine (22.8 mg, 0.226 mmol) refluxed in anhydrous THF (20 mL) for 18 hours to form the intermediate followed by 3-(dimethylamino)-propylamine (23.1 mg, 0.226 mmol) and refluxed for a further 5 hours to form the title compound. Work-up as in
  • Example 105 l-(3- ⁇ itrophenyl)-l-benzyl-3-(3-dimethylamino propyl) urea (CFM2270) Prepared as in Example 100 using 4-nitrophenyl chloroformate (66.0 mg, 0.328 mmol), N-benzyl-3-nitroaniline (50.0 mg, 0.219 mmol) and triethylamine (33.0 mg,
  • Example 106 l-Benzyl-l-(4-methyI-3-pyridinyl)-3-(3-dimethylamino propyl) urea (CFM2271) Prepared as in Example 100 using 4-nitrophenyl chloroformate (76.0 mg, 0.378 mmol), 2-benzylamino-4-methyl-pyridine (50.0 mg, 0.25 mmol) and triethylamine (38.0 mg, 0.378 mmol) refluxed in anhydrous THF (20 mL) for 5 hours to form the intermediate followed by 3-(dimethylamino)propylamine (38.0 mg, 0.378 mmol) and refluxed for a further 18 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 to 50 % MeOH (in CHC1 3 ) to give the title compound.
  • Example 100 Prepared as in Example 100 using 4-nitrophenyl chloroformate (62.0 mg, 0.308 mmol), N-methyl-3,5-bis(trifluoromethyl)aniline (50.0 mg, 0.206 mmol) and triethylamine (31.0 mg, 0.308 mmol) refluxed in anhydrous THF (20 mL) for 5 hours to form the intermediate followed by 3-(dimethylamino)propylamine (31.5 mg, 0.308 mmol) and refluxed for a further 18 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 to 40 % MeOH (in CHC1 3 ) to give the title compound.
  • Example 109 4-Nitrophenyl chloroformate (61.5 mg, 0.31 mmol), 5-chloro-2-(methylamino)- benzophenone (50.0 mg, 0.20 mmol) and triethylamine (30.80 mg, 0.31 mmol) were refluxed for 5 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (32.0 mg, 0.31 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC1 3 ) to give the title compound.
  • Example 109 l-(2-Chloro-4-trifluoromethylphenyl)-3-(3-dimethylaminopropyl) urea
  • Example 100 4-Nitrophenyl chloroformate (77.0 mg, 0.39 mmol), 4-amino-3-chloro- benzotrifluoride (50.0 mg, 0.26 mmol) and triethylamine (38.0 mg, 0.39 mmol) were refluxed for 18 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (38.0 mg, 0.39 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC1 3 ) to give the title compound.
  • Example 100 4-Nitrophenyl chloroformate (84.0 mg, 4.19 mmol), 3-amino-5- fluorobenzotrifluoride (50.0 mg, 0.28 mmol) and triethylamine (42.0 mg, 4.19 mmol) were refluxed for 18 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (42.0 mg, 4.19 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC1 3 ) to give the title compound.
  • Example 112 4-Nitrophenyl chloroformate (3.13 g, 15.54 mmol), 3-amino-l-(N-tert-butoxy- carbonyl)benzylamine (2.30 g, 10.36 mmol) and triethylamine (1.56 g, 15.54 mmol) was refluxed for 18 hours in anhydrous THF (100 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)propylamine (1.58 g, 15.54 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up same as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC1 3 ) to give the title compound.
  • Example 112 4-Nitrophenyl chloroformate (3.13 g, 15.54 mmol), 3-amino-l-(N-tert-butoxy- carbonyl)benzylamine
  • N-(3-Dimethylamino-propyl)-2-[l-(4-fluorobenzoyl]-benzamide (CFM2262) 2-(4-Fluorobenzoyl)benzoic acid (1.25 g, 5.12 mmol), N,N-(diisopropyl)amino- methylpolystyrene resin (PS-DIEA), (4.30 g, 15.36 mmol), and O-(7-azabenzotriazol-l- yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (1.95 g, 5.12 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes.
  • PS-DIEA N,N-(diisopropyl)amino- methylpolystyrene resin
  • HATU O-(7-azabenzotriazol-
  • 2-(4-Chlorobenzoyl)-benzoic acid (1.25 g, 4.80 mmol), N,N-(diisopropyl)amino- methylpolystyrene resin (PS-DIEA), (4.00 g, 14.38 mmol), and O-(7- azabenzotriazol- 1 -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (1.82 g, 4.80 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes.
  • PS-DIEA N,N-(diisopropyl)amino- methylpolystyrene resin
  • HATU O-(7- azabenzotriazol- 1 -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate
  • 2-(2-Phenylsulfamoyl-phenylsulfanyl)-benzoic acid (1.10 g, 2.60 mmol), NN- (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (2.18g, 7.78 mmol), and O- (7-azabenzotriazol-l -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (0.98 g, 2.6 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes.
  • PS-DIEA diisopropyl)amino-methylpolystyrene resin
  • HATU O- (7-azabenzotriazol-l -yl)-N,N,N,N-tetramethyluronium hexafluorophosphate
  • 2-Phenoxybenzoic acid (1.50 g, 7.00 mmol) was stirred in anhydrous toluene (50 mL) at 50 °C under nitrogen.
  • triethylamine (0.71 g, 7.00 mmol) and the temperature was increased to 80 °C at which stage diphenylphosphorylazide (DPP A) (1.92 g, 7.00 mmol) was added and the mixture was left to stir at this temperature for 5 hours.
  • DPP A diphenylphosphorylazide
  • 3- (dimethylamino)propylamine (0.71 g, 7.00 mmol) was added and the mixture was left to stir at 80 °C overnight under nitrogen.
  • Activity Example 1 Compounds of the invention were assayed to determine their ability to activate sGC.
  • the assay employed was an enzyme immunoassay to measure changes in cGMP.
  • IBMX enzyme immunoassay to measure changes in cGMP.
  • To perform the assay recombinant soluble Guanylate cyclase was added to 1.1 mg/ml IBMX, 2.6 mg/ml GTP, 667 nM DeaNO and the test compound (lO ⁇ M). The mixture was then incubated at room temperature for 10 minutes.
  • Compounds were formulated in DMSO diluted in Tris HCI (pH 7.4) buffer and with a final DMSO concentration of ⁇ 0.5%.
  • BiotrakTM cGMP enzyme immunoassay system commercially available from AmershamTM was used.
  • the assay is based on the competition between unlabelled cGMP and a fixed quantity of peroxidase labelled cGMP for a limited amount of cGMP specific antibody.
  • the peroxidase ligand that is bound to the antibody is immobilised on precoated microtitre wells.
  • the amount of labelled cGMP is determind using a one pot stabilised substrate.
  • the concentration of unlabelled cGMP in a sample is determined by interpolation from a standard curve.
  • Tables 4 to 7 The results are shown in Tables 4 to 7.
  • Tables 6 and 7 relate to commercially available compounds.
  • IC 50 values were measured as set out below.
  • PGI 2 (0.15 ⁇ g/ml) added and centrifuged at 950 g for 10 mins to sediment the platelets.
  • the resultant platelet poor plasma (PPP) was discarded and the platelet pellet was resuspended in an equal volume of Tyrodes buffer by gently pipetting up and down.
  • the suspension was centrifuged at 870 g for lOmins at 4 °C.
  • the supernatant was discarded and the platelet pellet was resuspended in an equal volume of Tyrodes buffer as before.
  • the platelets were counted (using a Coulter Counter model T540 (address)) and normalised to 250,000cells/ ⁇ l using Tyrodes.
  • the resultant suspension was placed on ice for approximately 1 hour until use.
  • Platelet A says Platelet aggregation was monitored using either a Chrono-Log model 560-CA dual channel ormodel 570-4S four channel aggregometer (Chrono-Log Co ., Havertown, PA). Aggregation was analysed by using 0.5 mL aliquots of the platelet suspension at 37 °C using % light transmittance.
  • the amplitude of each aggregatory response was used to plot dose-response curves.
  • the concentration of drug that inhibited collagen-induced platelet aggregation by 50% (IC 50 ) was calculated from the dose-response curves.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'utilisation d'un composé de la formule (I), ou d'un sel pharmaceutiquement acceptable de ce dernier, dans la fabrication d'un médicament utilisé pour activer la guanylate cyclase soluble, dans laquelle : R1 et R2 sont les mêmes ou différents et chacun représente un groupe alkyle en C1-C6, ou R1 et R2 forment ensemble un groupe alkylène en C3-C6 ; Z est un groupe alkylène en C1-C4 ; P est une liaison directe ou un fragment -X-, -Y-, -W-, -XY-, -YW- ou XYW, dans laquelle W est -O-, -S-, ou -NR3, R3 étant hydrogène ou alkyle en C1-C6 ; Y est un fragment -U-V- dans lequel V est une liaison directe ou un groupe alkylène en C1-C6 et U est -CS-, -CO-, -S(O)2- or -C(=NR)-, où R est hydrogène, hydroxy ou alkyle en C1-C6 ; X est -O- or -NR6-, où R6 est hydrogène, alkyle en C1-C6, alcényle en C2-C6, alkynyle, aryle ou hétéroaryle en C2-C6 ; et R4 est alkyle en C1-C6, alcényle en C2-C6, alkynyle, aryle, hétéroaryle, carbocyclyle, hétérocyclyle, un groupe R-A en C2-C6 dans lequel R est -(C1-C6 alkyle)-, -(C2-C6 alcényle)- ou -(C2-C6 alkynyle)- et A est aryle, hétéroaryle, carbocyclyle, hétérocyclyle, ou R4 est un groupe -COR', -CO2R', -S(O)2R' or -CONR'R' dans lequel R' est hydrogène, alkyle en C1-C6, alcényle en C2-C6, ou alkynyle en C2-C6, et R'' est aryle, hétéroaryle, carbocyclyle ou hétérocyclyle.
EP00973061A 1999-11-05 2000-11-06 Activateurs de la guanylate cyclase soluble Withdrawn EP1237849A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9926286.7A GB9926286D0 (en) 1999-11-05 1999-11-05 Activators of soluble guanylate cyclase
GB9926286 1999-11-05
US20138200P 2000-05-02 2000-05-02
US201382P 2000-05-02
PCT/GB2000/004249 WO2001032604A1 (fr) 1999-11-05 2000-11-06 Activateurs de la guanylate cyclase soluble

Publications (1)

Publication Number Publication Date
EP1237849A1 true EP1237849A1 (fr) 2002-09-11

Family

ID=26316060

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00973061A Withdrawn EP1237849A1 (fr) 1999-11-05 2000-11-06 Activateurs de la guanylate cyclase soluble

Country Status (5)

Country Link
EP (1) EP1237849A1 (fr)
JP (1) JP2003513064A (fr)
AU (1) AU1161601A (fr)
CA (1) CA2389773A1 (fr)
WO (1) WO2001032604A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014084312A1 (fr) * 2012-11-30 2014-06-05 アステラス製薬株式会社 Composé imidazopyridine

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1300401B1 (fr) * 2000-06-30 2009-12-09 Dainippon Sumitomo Pharma Co., Ltd. Dérivés de thiazole utiles commes des agents antiinflammatoires
JP2003081937A (ja) * 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
ES2373875T3 (es) 2002-03-05 2012-02-09 Transtech Pharma, Inc. Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage.
DE10216145A1 (de) * 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
US20040121994A1 (en) * 2002-12-20 2004-06-24 Anderson Steven N. Novel amides that activate soluble guanylate cyclase
AU2004224807A1 (en) 2003-03-24 2004-10-07 Axikin Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfomamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
JP2007084437A (ja) * 2003-12-26 2007-04-05 Dai Ichi Seiyaku Co Ltd アミノアルキルピラゾール誘導体
ES2383115T3 (es) * 2004-01-09 2012-06-18 Eli Lilly And Company Compuestos de tiofeno y furano
WO2005089068A2 (fr) * 2004-03-24 2005-09-29 Rimonyx Pharmaceuticals Ltd. Compositions pharmaceutiques comprenant des derives de quinazolinecarboxamide anti-inflammatoires
WO2006089076A2 (fr) * 2005-02-18 2006-08-24 Neurogen Corporation Thiazole amides, imidazole amides et analogues associes
DE102005011534A1 (de) * 2005-03-10 2006-09-21 Merck Patent Gmbh Chromen-4-on-Derivate
DE102005047945A1 (de) * 2005-07-16 2007-01-18 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen
EP1991528A2 (fr) * 2006-01-18 2008-11-19 Siena Biotech S.p.A. Modulateurs de la sous-unité alpha 7 du récepteur nicotinique de l'acétylcholine et leurs applications thérapeutiques
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
BRPI0816382A2 (pt) * 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
DE102008018675A1 (de) * 2008-04-14 2009-10-15 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung
EP2334380B1 (fr) * 2008-05-30 2021-09-01 Mitologics Molécules ant-ligands et applications biologiques
CA2772797C (fr) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Derives d'imidazole substitues
CN102892754A (zh) 2010-03-17 2013-01-23 埃克希金医药品有限公司 芳基磺酰胺ccr3拮抗剂
CN102250006B (zh) * 2011-05-12 2014-03-05 范如霖 3-吡唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
EP2716642B1 (fr) 2011-05-30 2016-07-20 Astellas Pharma Inc. Composé imidazopyridine
JP2017529330A (ja) * 2014-08-14 2017-10-05 バイエル・ファルマ・アクティエンゲゼルシャフト 置換キノリン−４−カルボキサミドおよびその使用
CN106831494B (zh) * 2017-03-14 2018-04-17 青岛科技大学 一种邻酰胺基二苯脲类化合物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE890958C (de) * 1940-06-11 1953-09-24 Bayer Ag Verfahren zur Herstellung von Sulfonamidverbindungen
US2553093A (en) * 1947-11-04 1951-05-15 Rhone Poulenc Sa Aminoalkylethanesulfonamide
US2628224A (en) * 1951-01-16 1953-02-10 Du Pont Vinyl dialkylaminohydrocarbonamides
DE1020636B (de) * 1954-11-12 1957-12-12 Geigy Ag J R Verfahren zur Herstellung von 3-Phenyl-7-acylamino-cumarinen
US2777853A (en) * 1955-09-06 1957-01-15 Hoffmann La Roche Mercapto benzothiazole compounds
US3170955A (en) * 1958-04-25 1965-02-23 Abbott Lab Amino and halogen substituted-n-diloweralkylamino-alkyl-benzamides
DE1156080B (de) * 1959-02-07 1963-10-24 Laeaeketehdas Orion Oy Verfahren zur Herstellung von aromatischen, in den beiden Orthostellungen substituierten Saeureamiden
FR1586112A (fr) * 1968-05-27 1970-02-13
IE47458B1 (en) * 1977-11-07 1984-03-21 Leo Pharm Prod Ltd Quinolylguanidine derivatives
DE4038128A1 (de) * 1990-11-27 1992-06-04 Schering Ag 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2670780B1 (fr) * 1990-12-20 1993-07-09 Synthelabo Derives de 4-(acylamino)benzopyranes, leur preparation et leur application en therapeutique.
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
DE19836697A1 (de) * 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0132604A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014084312A1 (fr) * 2012-11-30 2014-06-05 アステラス製薬株式会社 Composé imidazopyridine

Also Published As

Publication number Publication date
AU1161601A (en) 2001-05-14
JP2003513064A (ja) 2003-04-08
WO2001032604A1 (fr) 2001-05-10
CA2389773A1 (fr) 2001-05-10

Similar Documents

Publication Publication Date Title
EP1237849A1 (fr) Activateurs de la guanylate cyclase soluble
TWI286550B (en) Benzophenones as inhibitors of reverse transcriptase
TWI417096B (zh) 用於發炎及免疫相關用途之苯基及吡啶基化合物
TWI242005B (en) Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE69432984T2 (de) Therapeutische substituierte guanidine
EP1383750B1 (fr) Derives d'uree en tant qu'antagonistes d'alpha 4 integrine
US8039493B2 (en) Biaryl sulfonamide derivatives
KR100252453B1 (ko) 에이치아이브이 및 관련 바이러스 억제를 위한 화합물 및 방법
US20060223879A1 (en) Non-steroidal farnesoid x receptor modulators
US20020143186A1 (en) Glucagon antagonists/inverse agonists
US6762176B1 (en) 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them
JP4644714B2 (ja) 新規なシクロヘキサン誘導体
US20070135499A1 (en) Hydrazide compounds
AU2008205047A2 (en) 6-aminoisoquinoline compounds useful as kinase modulators
KR20020014797A (ko) 글루카곤 길항제/역 아고니스트
MXPA04005864A (es) Derivados de charcona y su uso para tratar enfermedades.
PT934301E (pt) Aminotiofenocarboxamidas
UA75891C2 (en) Pharmaceutically active sulfonamides derivatives having either lipophilic fragments and those capable to ionize as inhibitors of protein- jun-kinases, a pharmaceutical composition, a method for obtaining these compounds (variants) and intermediary compounds
DE19541146A1 (de) Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren
KR101872553B1 (ko) Trpm8 수용체 길항제들
JP4885393B2 (ja) 医薬として活性なスルホニル・ヒドラジド誘導体
KR102132744B1 (ko) 당뇨병 치료에 유용한 이미다조피리딘 유도체들
HUT72601A (en) 2,5-diaryl tetrahydro-thiophenes-furans and analogs for the treatment of inflammatory and immune disorders
JP2004513936A (ja) グルカゴンアンタゴニスト／逆アゴニスト
AU769071B2 (en) Benzenic sulphonamide derivatives and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030602